Identifying novel bioactive compounds is hard, which makes discovering new medicines and crop protection chemicals slow and expensive. Erebagen has developed a platform that enables it to engineer soil bacteria to produce new bioactive natural products with hit-rates 20x-better than synthetic chemicals currently being used in industrial screens.
Erebagen’s Gen2NCE platform combines bioinformatics and synthetic biology techniques which overcome the two major challenges of traditional natural product discovery – rediscovery and developability. Our platform has two offerings:
ii) Create modified biosynthetic pathways which deliver structural variants of these natural products. (“Diversify”)
Recent market comparables indicate that natural product discovery is undergoing a resurgence and that significant value can be obtained through partnerships with large pharma partners who are seeking privileged access to new natural products to feed into their drug development pipelines, e.g.
We have identified five early-adopters through ICURe who want to engage in screening partnerships using our existing compound collection and a longer list of larger partners from both the pharma and agrochemical sectors that have indicated interest in partnering as our library grows.
In combination, Erebagen’s platform offerings open up revenue streams from i) chemical library sales; ii) co-discovery and development partnerships with pharmaceutical and agrochemical companies.
Chairman: New Hire
CSO & Co-founder: Dr Doug Roberts
Scientific Advisor & Co-founder: Prof. Greg Challis
Business Advisors: Dr Pete Charlton, Dr Rupert Osborn
Contact: [email protected] | https://www.erebagen.com (in development)